Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non–small cell lung cancer without tumor PD‐L1 expression: A pooled analysis of 3 randomized controlled trials

BACKGROUND: Pembrolizumab plus platinum‐based chemotherapy has demonstrated improved clinical outcomes over chemotherapy alone in patients with previously untreated advanced/metastatic non–small cell lung cancer (NSCLC), regardless of tumor programmed death ligand 1 (PD‐L1) expression. This study po...

Descripción completa

Detalles Bibliográficos
Autores principales: Borghaei, Hossein, Langer, Corey J., Paz‐Ares, Luis, Rodríguez‐Abreu, Delvys, Halmos, Balazs, Garassino, Marina C., Houghton, Baerin, Kurata, Takayasu, Cheng, Ying, Lin, Jianxin, Pietanza, M. Catherine, Piperdi, Bilal, Gadgeel, Shirish M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7692929/
https://www.ncbi.nlm.nih.gov/pubmed/32914866
http://dx.doi.org/10.1002/cncr.33142

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7692929/
https://www.ncbi.nlm.nih.gov/pubmed/32914866
http://dx.doi.org/10.1002/cncr.33142

Ejemplares similares